AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01084525
Drug: OTO-104 (steroid) 12 mg
RxNorm normalized name: DB-OTO
DrugBank: DB-OTO (DB18278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential dose cohort escalation to OTO-104 12 mg dose cohort will occur pending the safety evaluation of 28 day follow up safety data for the OTO-104 3 mg dose cohort. OTO-104 12mg dose cohort is also a single intratympanic injection.
Trial: NCT03827200
Drug: Ambrisentan
RxNorm normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ambrisentan will be administered subcutaneously at the Hospital on the days of HVPG deterination and taken orally at home between visits.
Trial: NCT01119651
Drug: Tazarotene (Patch application in Challenge Phase)
RxNorm normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: There are 2 phases in this study. The induction phase will include 6 days of patch application to the subject's back. Patches will be removed daily and irradiated. Patch applications will be placed on the same sites, unless a strong reaction is observed. The induction phase will be followed by a rest period followed by the Challenge Phase which consists of a 24-hr application of 3 sets of 3 patches (Set C, Set D, and Set E) applied to naïve sites on the subject's back. Each set of patches will consist of a tazarotene foam patch, a vehicle foam patch, and a blank patch. After 24 hrs, Set D patch sites will be evaluated and irradiated with UVA/UVB light. Set C patch sites will be evaluated and irradiated with UVA, UVB light and visible light. Set E patch sites will be evaluated \& will serve as nonirradiated controls. Patch sites will be evaluated 1 hr after patch removal and during follow up visits at 24 hrs, 48 hrs, and 72 hrs after removal of the final patch in Set E.
Trial: NCT01266369
Drug: masitinib
RxNorm normalized name: masitinib
DrugBank: Masitinib (DB11526)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04011930
Drug: cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
Trial: NCT01349270
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months
Trial: NCT01083732
Drug: dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental dose chosen based on age and weight
Trial: NCT03261466
Drug: Bifidobacterium breve BR03 and Bifidobacterium breve B632
DrugBank: Bifidobacterium breve (DB16549)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00084435
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 IV, Day 1, q 21 days for 3 cycles
Trial: NCT00084435
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mg/m2 IV, Day 1, 1 7 days for 6 doses
Trial: NCT00955162
Drug: Buprenorphine (Subutex)
RxNorm normalized name: buprenorphine Sublingual Tablet [Subutex]
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sublingual tablet
Trial: NCT00955162
Drug: Buprenorphine/naloxone (Suboxone)
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sublingual tablet
Trial: NCT03926026
Drug: Fluticasone Propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NCX 4251 Ophthalmic Suspension, 0.1%
Trial: NCT01105975
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered daily by mouth for 12 weeks
Trial: NCT00238485
Drug: Licarbazepine
RxNorm normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02433587
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take Aspirin 81 mg
Trial: NCT02433587
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will take Clopidogrel 75 mg
Trial: NCT00856700
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive intraarterial infusion of GLP-1 (20 pmol/ml solution) for 100 min.
Trial: NCT04325217
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Capsules
Trial: NCT04898569
Drug: Ferinject
RxNorm normalized name: epinephrine
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose injection
Trial: NCT00371345
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, Oral, 70 mg, twice daily, as long as the participant benefits (average \<6 months)
Trial: NCT00371345
Drug: Dasatinib 100 mg
RxNorm normalized name: dasatinib 100 MG
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, Oral, 100mg, twice daily, as long as the participant benefits (average \<6 months)
Trial: NCT00661336
Drug: buthionine sulfoximine
RxNorm normalized name: Buthionine sulfoximine
DrugBank: Buthionine sulfoximine (DB12870)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00661336
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02347332
Drug: Vinflunine
RxNorm normalized name: vinflunine
DrugBank: Vinflunine (DB11641)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01215747
Drug: KIACTA (eprodisate disodium)
RxNorm normalized name: BALSALAZIDE DISODIUM
DrugBank: Eprodisate (DB06405)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally 1 to 3 capsules (Kiacta 400 mg) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases.
Trial: NCT00065182
Drug: Topotecan/Docetaxel combination
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03912909
Drug: Empagliflozin Oral Tablet [Jardiance]
RxNorm normalized name: empagliflozin Oral Tablet [Jardiance]
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases
Trial: NCT02432066
Drug: GTS-21
RxNorm normalized name: GTS-21
DrugBank: GTS-21 (DB05708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTS-21 is a partial alpha7 nicotinic agonist. GTS-21 will be compounded by the UF investigational pharmacy, and administered orally.
Trial: NCT02977832
Drug: Alfuzosin
RxNorm normalized name: Alfuzosin
DrugBank: Alfuzosin (DB00346)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10Mg Oral Tablet, Extended Release
Trial: NCT02930317
Drug: Recombinant Factor VIII (50 IU/kg)
RxNorm normalized name: factor VIII Injection [Recombinate]
DrugBank: PEGylated Recombinant Factor VIII (DB16093)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02930317
Drug: Recombinant Factor VIII (On-demand treatment)
RxNorm normalized name: factor VIII Injection [Recombinate]
DrugBank: PEGylated Recombinant Factor VIII (DB16093)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01170845
Drug: sivelestat sodium hydrate
RxNorm normalized name: carbazochrome sodium sulfonate hydrate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: saline or sivelestat sodium hydrate intravenously for 7 days starting the beginning of surgery
Trial: NCT03387826
Drug: Ticagrelor 60 mg
RxNorm normalized name: ticagrelor 60 MG
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 60 mg twice daily
Trial: NCT03387826
Drug: Prasugrel 5mg
RxNorm normalized name: Prasugrel 5mg Oral tablet
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prasugrel 5 mg once daily
Trial: NCT00065182
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01267643
Drug: Alefacept
RxNorm normalized name: Alefacept
DrugBank: Alefacept (DB00092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose Escalation Schedule~Level -1 5 mg IV once weekly~Level 1 7.5 mg IV once weekly~Level 2 10 mg IV once weekly~Level 3 12.5 mg IV once weekly
Trial: NCT03783416
Drug: Ixazomib (NINLARO®) capsules / Matching placebo capsules
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will be treated for a maximum of 24 months
Trial: NCT00179751
Drug: CC-5013
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00179751
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01446497
Drug: Brimonidine/Timolol mixed combination
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Twice per day, 1 drop at each time
Trial: NCT01446497
Drug: Timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Twice per day, 1 drop at each time
Trial: NCT01562834
Drug: somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months (randomised trial period) followed by an 12-month open-label trial period with somatropin.
Trial: NCT00229658
Drug: pramlintide acetate
RxNorm normalized name: Pramlintide Acetate
DrugBank: Pramlintide (DB01278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection prior to each major meal
Trial: NCT04621435
Drug: Gallium-68 labelled (68Ga-) FAP-2286
RxNorm normalized name: Gallium 68 dotatate
DrugBank: Gallium nitrate (DB05260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging
Trial: NCT04621435
Drug: Copper-64 labeled (64Cu-) FAP-2286
RxNorm normalized name: copper (64Cu) dotatate
DrugBank: Copper (DB09130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose will be 3.5 to 5.5 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging
Trial: NCT02118311
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 30mg/m\^2 IV over 1 hour on days -6 through -2 from transplant
Trial: NCT02796729
Drug: Gadovist (Gadobutrol)
RxNorm normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).
Trial: NCT02796729
Drug: 50% dextrose solution
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for intravenous injection.
Trial: NCT01630226
Drug: Neoadjuvant Cisplatin Chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be treated with cisplatin chemotherapy at a dose of 75mg/m2 every three weeks for a total of four cycles (4 cycles of neoadjuvant chemotherapy).
Trial: NCT02157116
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02157116
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02157116
Drug: Pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00370383
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: erlotinib 150 mg/day once daily
Trial: NCT00370383
Drug: Satraplatin
RxNorm normalized name: Satraplatin
DrugBank: Satraplatin (DB04996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: satraplatin 100 mg/m2 orally once daily for 5 consecutive days (days 1-5)followed by erlotinib 150mg/day for 14 consecutive days (days 8-21).~Satraplatin JM-216, bis-aceto-ammine dischlorocyclohexylamine platinum)is a third-generation platinum analogue with activity following oral administration. The molecular formula for satraplatin is C10H22N2Cl2O4Pt, which is structured as an octahedral platinum compound.
Trial: NCT00093496
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00093496
Drug: tanespimycin
RxNorm normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00402428
Drug: albumin interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 900 mcg or 1200mcg every two week for 48 weeks
Trial: NCT00402428
Drug: peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 mcg once a week for 48 weeks
Trial: NCT00402428
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/day(for subjects \<75kg) or 1200 mg/day (for subjects~=,\> 75kg)
Trial: NCT02022657
Drug: Truvada
RxNorm normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP
Trial: NCT02150616
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
Trial: NCT02150616
Drug: Sham oxygen (room air)
RxNorm normalized name: air
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
Trial: NCT02831231
Drug: xanomeline tartrate
RxNorm normalized name: xanomeline tartrate
DrugBank: Xanomeline (DB15357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xanomeline tartrate, 75 mg capsule, TID
Trial: NCT02831231
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: trospium chloride, over encapsulated 20 mg tablet, BID
Trial: NCT02079649
Drug: Dexamethasone Ophthalmic Suspension, 0.1%
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02079649
Drug: AL-53817 Vehicle
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredients used for masking purposes
Trial: NCT01408394
Drug: Ecopipam immediate release form
RxNorm normalized name: Ecopipam
DrugBank: Ecopipam (DB12273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet containing 100 mg of the immediate release form of ecopipam
Trial: NCT02974322
Drug: GED-0301
RxNorm normalized name: GED-0507-34-Levo
DrugBank: GED-0507-34-Levo (DB16109)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GED-0301
Trial: NCT00140725
Drug: Lamivudine plus Polyethylene glyco-interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00140725
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01515241
Drug: CER-001
RxNorm normalized name: CER-001
DrugBank: CER-001 (DB18538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly injection
Trial: NCT01500200
Drug: ALKS 5461
RxNorm normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two active tablets, given daily
Trial: NCT03053505
Drug: Vancomycin or Fidaxomicin
RxNorm normalized name: Fidaxomicin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Randomized group FAB: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with antibiotics (vancomycin per os 125mg four times a day for 10 days) in this group. In case of treatment failure changes in antibiotic regime (e.g. fidaxomicin per os 200mg per two times a day for 10 days) will be allowed in the line with the recommendations of current CDI treatment guidelines(13).
Trial: NCT03680638
Drug: Tempol
RxNorm normalized name: Tempol
DrugBank: Tempol (DB12449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention is meant to assess the impact of superoxide on vasodilator responses by scavenging available superoxide.
Trial: NCT03680638
Drug: Apocynin
RxNorm normalized name: Apocynin
DrugBank: Apocynin (DB12618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme NADPH oxidase.
Trial: NCT03680638
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme xanthine oxidase.
Trial: NCT03205566
Drug: Raltegravir 400Mg Tab
RxNorm normalized name: RALTEGRAVIR 400MG TAB
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bd for 7 days
Trial: NCT03205566
Drug: Lamivudine 150Mg Tablet
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: + Raltegravir 400Mg tablet bd for 7 days
Trial: NCT03213145
Drug: intraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive itraconazole once daily from Day 5 through Day18
Trial: NCT03213145
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive rifampin once daily from Day 5 through Day 16
Trial: NCT03213145
Drug: EDP 305
RxNorm normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive EDP 305 once daily on Day 1 and Day 14
Trial: NCT02324296
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEI regimen may be a possible therapeutic option, with high activity and an acceptable toxicity profile.
Trial: NCT03656042
Drug: Filgrastim (75mcg/0.3ml)
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects who meet all eligible requirements for entry into the study will be randomized into one of the two treatment groups in 1:1 ratio as shown below:~1. 10 microgram/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks; repeat dosing regimen every 12-weekly (12 weeks / cycle) for 2 cycles~2. Non-treatment
Trial: NCT00621673
Drug: Kogenate (BAY 14-2222)
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihemophilic factor (recombinant) 20-40 IU/ kg based on body weight of rFVIII, IV, 3 times a week
Trial: NCT01260896
Drug: Venlafaxine Hydrochloride
RxNorm normalized name: Venlafaxine Hydrochloride
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg Extended-Release Capsule
Trial: NCT03355573
Drug: Bimekizumab
RxNorm normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Bimekizumab at a prespecified dose.
Trial: NCT02624141
Drug: Epoetin Beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
Trial: NCT00856362
Drug: Moxidectin
RxNorm normalized name: moxidectin
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00856362
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01953692
Drug: Lenalidomide 20 mg
RxNorm normalized name: lenalidomide 20 MG
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral capsule
Trial: NCT01953692
Drug: Lenalidomide 25 mg
RxNorm normalized name: lenalidomide 25 MG
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral capsule
Trial: NCT02275611
Drug: intranasal oxytocin spray
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of oxytocin in a nasal spray